24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs

OBJECTIVE: To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2010-06, Vol.33 (6), p.1176-1178
Hauptverfasser:	Swinnen, Sanne G, Dain, Marie-Paule, Aronson, Ronnie, Davies, Melanie, Gerstein, Hertzel C, Pfeiffer, Andreas F, Snoek, Frank J, DeVries, J. Hans, Hoekstra, Joost B, Holleman, Frits
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Biological and medical sciences Clinical trials Comparative analysis Diabetes Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetes. Impaired glucose tolerance Dosage and administration Drug Administration Schedule Drug therapy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - pharmacology Insulin - administration & dosage Insulin - analogs & derivatives Insulin - pharmacology Insulin - therapeutic use Insulin Detemir Insulin Glargine Insulin, Long-Acting Medical sciences Metabolic diseases Miscellaneous Original Research Patient outcomes Public health. Hygiene Public health. Hygiene-occupational medicine Quality of life Studies Treatment Outcome Type 2 diabetes Weight Gain - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	OBJECTIVE: To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C
ISSN:	0149-5992 1935-5548
DOI:	10.2337/dc09-2294